Welcome to Cell & Gene Live – An interactive forum to discuss some of the most important technologies and trends impacting cell and gene therapies.
Throughout the year, our Chief Editor, Erin Harris, sits down with industry experts to discuss how biotechs can tackle some of today’s biggest challenges they may face in driving progress in the cell and gene therapy field. Even better, the audience gets ask questions during the presentation. Each Cell & Gene Live session is archived and can be accessed at any time by registered site users.
TACKLING THE CELL & GENE MANUFACTURING TALENT CRUNCH
-
![21_02_BPO_CGTalentCrunch_1920x1080]( "Tackling The Cell & Gene Manufacturing Talent Crunch")
Tackling The Cell & Gene Manufacturing Talent CrunchJoin Project Farma and Precision ADVANCE leaders Anshul Mangal and John Khoury for a discussion with BioProcess Online Chief Editor Matt Pillar to address solutions to the biotherapeutic and cell and gene therapy process and manufacturing talent gap.
CAN INNOVATION DRIVE DOWN CELL THERAPY MANUFACTURING COSTS?
-
![21_01_CG_InnovationCellManufaturing_1920x1080]( "Can Innovation Drive Down Cell Therapy Manufacturing Costs?")
Can Innovation Drive Down Cell Therapy Manufacturing Costs?The high cost of producing new cell and gene therapies is one of the largest issues facing the industry. After launching Kymriah and Yescarta, Novartis’ price tags were $475,000 and $375,000, respectively. Advancements in manufacturing are driving costs down, but not at the required pace.
THE FUTURE OF CRISPR-ENGINEERED STEM CELL THERAPIES
-
![20_11_CG_CRISPRStemCellResearch_1920x1080]( "The Future of CRISPR-Engineered Stem Cell Therapies")
The Future of CRISPR-Engineered Stem Cell TherapiesTo learn more about CRISPR gene editing, Cell and Gene Chief Editor, Erin Harris, sat down with Sadik Kassim, Chief Technical Officer at Vor Biopharma to discuss the benefits of CRISPR-engineered stem cell therapies, the challenges and feasible solutions, what’s next, and more.
- The History of CRISPR Gene Edited Therapies
- The Future of CRISPR-Engineered Stem Cell Therapies: 3 Clinical Trial Examples
- The Ethical Implications Of Editing A Genome
- The Challenges Associated With CRISPR Gene Editing
- The Patient Perspective Of CRISPR-Engineered Stem Cell Therapies
- The Future of CRISPR-Engineered Stem Cell Therapies: Adverse Effects In Clinical Trials
- The Future of CRISPR-Engineered Stem Cell Therapies: Technology & Platforms
- The Permanency Of Gene Therapy
- The Future of CRISPR-Engineered Stem Cell Therapies: Digestive Disease Studies
- The Misconceptions Of CRISPR Gene Edited Stem Cell Therapies
- Will CRISPR Change Modern Medicine?
- The Future of CRISPR-Engineered Stem Cell Therapies: Outsourcing vs. In-House
- What The Gene Therapy Sector Doesn't Understand About CRISPR?
- The Future of CRISPR-Engineered Stem Cell Therapies: Virtual Event Audience Q&A
Erin Harris
Click here to email Erin.
Erin Harris is chief editor of Cell & Gene and a contributing editor to Life Science Leader magazine. She studied English and psychology at Lafayette College and has 20+ years of experience in B2B publishing. Erin spent 10 years covering and reporting on the adoption of information technology from a B2B perspective. She’s written on technology topics ranging from Big Data and analytics to security and e-commerce. In each case, her reporting centered on innovations that improved operational efficiencies, fostered interdepartmental collaboration, or enhanced supply chains. Currently, she writes actionable information for professionals involved in the development and commercialization of cell and gene therapies. She covers the entire product lifecycle from basic research to commercialization. Erin has interviewed executives from Fortune 500 as well as startups. She has moderated panel discussions and has spoken at numerous industry events from large conferences to niche forums.